Clinical trial · Expanded Access
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
NCT03126617CI-TRIAL-00055263no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. When contacted by a treating physician, BMS will consider requests for providing early patient access to Elotuzumab in patients with multiple myeloma who are residents of Belgium, Thailand, Turkey, Argentina, and Colombia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Elotuzumab | Biological | Elotuzumab | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Specific eligibility criteria must be met for access outside of a clinical trial. These inclusion criteria include: * The illness must be serious or life threatening * There are no other viable options (including approved products or active clinical trials) * There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks based on what is known at the time * Other defined inclusion/exclusion criteria could be applicable.
References
Publications (0)
Data not yet available
No reference posted for this study.